On March 13, 2024, Lexeo Therapeutics, Inc., a clinical-stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, announced the closing of its previously announced private placement with total gross proceeds of approximately $95 million. The financing was co-led by Braidwell LP and Adage Capital Partners LP, with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management, Novo Holdings A/S, Invus, Laurion Capital Management, Longitude Capital, Omega Funds, and Woodline Partners LP.

Wilson Sonsini Goodrich & Rosati advised Lexeo Therapeutics on the transaction.

Lexeo intends to use net proceeds from the financing to fund advancement of ongoing clinical-stage programs, and for working capital and general corporate purposes. The proceeds from this financing, combined with current cash, cash equivalents, and marketable securities, are expected to fund operating and capital expenditures into 2027.

The Wilson Sonsini team that advised Lexeo on the transaction included Megan Baier, Jessica McBride, Carole Rosenberg, and Lauren Nilles.

For more information, please see Lexeo’s press release.